公开(公告)号：JP2000355600A

公开(公告)日：2000-12-26

申请号：JP2000126152

申请日：2000-04-26

Applicant: COR THERAPEUTICS INC

Inventor： RAMAKRISHNAN VANITHA ,  ESCOBEDO MARIA A ,  FRETTO LARRY J

IPC: A61K39/395 ,  A61K9/20 ,  A61K38/00 ,  A61K48/00 ,  A61P9/00 ,  A61P9/08 ,  A61P35/00 ,  A61P43/00 ,  C07K7/08 ,  C07K14/705 ,  C07K14/71 ,  C07K16/00 ,  C07K16/28 ,  C12N5/18 ,  C12N15/09 ,  C12N15/13 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531 ,  G01N33/566 ,  G01N33/577

Abstract: PROBLEM TO BE SOLVED: To obtain an antibody capable of inhibiting the PDGF(platelet derived growth factor) BB lag phase of cells expressing human β-PDGF in a defined concentration to a higher extent than a specific value and useful e.g. for the therapy and diagnosis of adult dyspnea syndrome-related pulmonary fibrosis or the like. SOLUTION: This antibody can specifically bind to a β-PDGF receptor not existing in the fifth extracellular Ig-like domain and inhibits the PDGF BB lag phase of cells expressing β-PDGF in an antibody concentration of 10 μg/mL to an extent of >80%. The antibody preferably inhibits the binding of the PDGF BB to cells expressing a β-PDGF receptor or binds to the extracellular Ig-like domain of a β-PDGF receptor. A composition comprising the antibody and a medicinally permissible excipient preferably is prepared. The daily dosage level of the antibody preferably is from 0.1 mg/kg to 10.0 mg/kg.

公开(公告)号：JP2000355548A

公开(公告)日：2000-12-26

申请号：JP2000126131

申请日：2000-04-26

Applicant: COR THERAPEUTICS INC

Inventor： RAMAKRISHNAN VANITHA ,  ESCOBEDO MARIA A ,  FRETTO LARRY J

IPC: A61K39/395 ,  A61K9/20 ,  A61K38/00 ,  A61K48/00 ,  A61P9/00 ,  A61P9/08 ,  A61P35/00 ,  A61P43/00 ,  C07K7/08 ,  C07K14/705 ,  C07K14/71 ,  C07K16/00 ,  C07K16/28 ,  C12N5/18 ,  C12N15/09 ,  C12N15/13 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531 ,  G01N33/566 ,  G01N33/577

Abstract: PROBLEM TO BE SOLVED: To obtain the subject composition useful for the treatments of restenosis, adult respiratory distress syndrome-related fibroid lung and the like by including an antibody specifically bindable to a specific growth factor receptor so as to be capable of specifically inhibiting the receptor's activation. SOLUTION: This composition is obtained by including an anti-platelet-derived growth factor(PDGF) receptor antibody at effective levels. This antibody is preferably a monoclonal antibody, preferably anti-PDGF-β-receptor antibody. The above composition is preferably a medicinal composition to inhibit the proliferation of smooth muscle cells at the lesion sites of blood vessel and- preferably comprises enough quantity of the anti-growth factor receptor antibody to inhibit mitosis induction and/or transfer of smooth muscle cells of blood vessel at the lesion sites, and also preferably the above antibody is selected from anti-PDGF-βreceptor antibodies. In the above composition, an aqueous carrier, conventional nontoxic solid carrier or the like can be used.

公开(公告)号：DK0584082T3

公开(公告)日：2000-10-16

申请号：DK92906305

申请日：1992-01-28

Applicant: UNIV CALIFORNIA ,  COR THERAPEUTICS INC

Inventor： WOLF DAVID ,  WILLIAMS LEWIS T ,  FRETTO LARRY J ,  GIESE NEILL A ,  ESCOBEDO JAIME A ,  TOMLINSON JAMES E

IPC: A61K39/395 ,  A61K38/00 ,  C07K7/04 ,  C07K14/00 ,  C07K14/705 ,  C07K14/71 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/566 ,  A01N1/02 ,  A61K37/02 ,  A61K38/18 ,  C07H15/12 ,  C07H17/00 ,  C07K3/00 ,  C07K13/00 ,  C07K14/475 ,  C07K15/00 ,  C07K17/00 ,  C12N5/00 ,  C12Q1/00 ,  C12Q1/68

Abstract: Defined constructs of modified human platelet-derived growth factor receptor polypeptides are provided. Extracellular region domain structures are identified and modifications and combinatorial rearrangements of the receptor segments are provided. Both cell bound and soluble forms of modified segments are made available, as are methods for assays using them, allowing for screening of ligand analogues.

公开(公告)号：AT193553T

公开(公告)日：2000-06-15

申请号：AT92906305

申请日：1992-01-28

Applicant: COR THERAPEUTICS INC ,  UNIV CALIFORNIA

Inventor： ESCOBEDO JAIME A ,  WILLIAMS LEWIS T ,  WOLF DAVID ,  TOMLINSON JAMES E ,  FRETTO LARRY J ,  GIESE NEILL A

IPC: A61K39/395 ,  A61K38/00 ,  C07K7/04 ,  C07K14/00 ,  C07K14/705 ,  C07K14/71 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/566 ,  C12Q1/68 ,  C07K14/475 ,  A61K38/18

Abstract: Defined constructs of modified human platelet-derived growth factor receptor polypeptides are provided. Extracellular region domain structures are identified and modifications and combinatorial rearrangements of the receptor segments are provided. Both cell bound and soluble forms of modified segments are made available, as are methods for assays using them, allowing for screening of ligand analogues.

公开(公告)号：SG72635A1

公开(公告)日：2000-05-23

申请号：SG1996004978

申请日：1992-12-01

Applicant: COR THERAPEUTICS INC

Inventor： RAMAKRISHNAN VANITHA ,  ESCOBEDO MARIA A ,  FRETTO LARRY J

IPC: A61K39/395 ,  A61K9/20 ,  A61K38/00 ,  A61K48/00 ,  A61P9/00 ,  A61P9/08 ,  A61P35/00 ,  A61P43/00 ,  C07K7/08 ,  C07K14/705 ,  C07K14/71 ,  C07K16/00 ,  C07K16/28 ,  C12N5/18 ,  C12N15/09 ,  C12N15/13 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531 ,  G01N33/566 ,  G01N33/577

公开(公告)号：CA2124958C

公开(公告)日：2007-02-13

申请号：CA2124958

申请日：1992-12-01

Applicant: COR THERAPEUTICS INC

Inventor： RAMAKRISHNAN VANITHA ,  ESCOBEDO MARIA A ,  FRETTO LARRY J

IPC: A61K39/395 ,  C12N15/13 ,  A61K9/20 ,  A61K38/00 ,  A61K48/00 ,  A61P9/00 ,  A61P9/08 ,  A61P35/00 ,  A61P43/00 ,  C07K7/08 ,  C07K14/705 ,  C07K14/71 ,  C07K16/00 ,  C07K16/28 ,  C07K16/42 ,  C07K19/00 ,  C12N5/12 ,  C12N5/18 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531 ,  G01N33/566 ,  G01N33/577

Abstract: The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerisation, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

公开(公告)号：GR3034267T3

公开(公告)日：2000-12-29

申请号：GR20000401954

申请日：2000-08-30

Applicant: COR THERAPEUTICS INC ,  ESCOBEDO JAIME A ,  WILLIAMS LEWIS T

Inventor： ESCOBEDO JAIME A ,  WILLIAMS LEWIS T ,  WOLF DAVID ,  TOMLINSON JAMES E ,  FRETTO LARRY J ,  GIESE NEILL A

IPC: A61K39/395 ,  A61K38/00 ,  C07K7/04 ,  C07K14/00 ,  C07K14/705 ,  C07K14/71 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/566 ,  C07H15/12 ,  C07H17/00 ,  C07K3/00 ,  C07K13/00 ,  C07K15/00 ,  C07K17/00 ,  A01N1/02 ,  C12Q1/00 ,  C12Q1/68 ,  C12N5/00

Abstract: Defined constructs of modified human platelet-derived growth factor receptor polypeptides are provided. Extracellular region domain structures are identified and modifications and combinatorial rearrangements of the receptor segments are provided. Both cell bound and soluble forms of modified segments are made available, as are methods for assays using them, allowing for screening of ligand analogues.

公开(公告)号：AU5580496A

公开(公告)日：1996-09-19

申请号：AU5580496

申请日：1996-06-03

Applicant: COR THERAPEUTICS INC ,  JAIME A ESCOBEDO ,  LEWIS T WILLIAMS

Inventor： ESCOBEDO JAIME A ,  WILLIAMS LEWIS T ,  WOLF DAVID ,  TOMLINSON JAMES E ,  FRETTO LARRY J ,  GIESE NEILL A

IPC: A61K39/395 ,  A61K38/00 ,  C07K7/04 ,  C07K14/00 ,  C07K14/705 ,  C07K14/71 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/566

Abstract: Defined constructs of modified human platelet-derived growth factor receptor polypeptides are provided. Extracellular region domain structures are identified and modifications and combinatorial rearrangements of the receptor segments are provided. Both cell bound and soluble forms of modified segments are made available, as are methods for assays using them, allowing for screening of ligand analogues.

公开(公告)号：CA2124958A1

公开(公告)日：1993-06-10

申请号：CA2124958

申请日：1992-12-01

Applicant: COR THERAPEUTICS INC

Inventor： RAMAKRISHNAN VANITHA ,  ESCOBEDO MARIA A ,  FRETTO LARRY J

IPC: A61K39/395 ,  A61K9/20 ,  A61K38/00 ,  A61K48/00 ,  A61P9/00 ,  A61P9/08 ,  A61P35/00 ,  A61P43/00 ,  C07K7/08 ,  C07K14/705 ,  C07K14/71 ,  C07K16/00 ,  C07K16/28 ,  C12N5/18 ,  C12N15/09 ,  C12N15/13 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531 ,  G01N33/566 ,  G01N33/577 ,  C07K16/42 ,  C07K19/00 ,  C12N5/12

Abstract: 2124958 9310805 PCTABS00022 The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerisation, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

公开(公告)号：EP0584082A4

公开(公告)日：1994-08-24

申请号：EP92906305

申请日：1992-01-28

Applicant: COR THERAPEUTICS INC ,  ESCOBEDO JAIME A ,  WILLIAMS LEWIS T

Inventor： ESCOBEDO JAIME A ,  WILLIAMS LEWIS T ,  WOLF DAVID ,  TOMLINSON JAMES E ,  FRETTO LARRY J ,  GIESE NEILL A

IPC: A61K39/395 ,  A61K38/00 ,  C07K7/04 ,  C07K14/00 ,  C07K14/705 ,  C07K14/71 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/566

CPC classification number: C07K16/2863 ,  A61K38/00 ,  C07K14/71 ,  C07K2319/00